GABRIEL JALLES: Open Payments
NPI 1821851494 · ORLANDO, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,072 in 107 payments from 19 companies in 2025. Trend: 2023 $0 · 2024 $1,363 · 2025 $3,072
Food & beverage: $3,072
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 48 | $1,241 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $279 |
| Otsuka America Pharmaceutical, Inc. | 9 | $269 |
| Corium, LLC | 14 | $234 |
| ABBVIE INC. | 6 | $215 |
| E.R. Squibb & Sons, L.L.C. | 5 | $187 |
| Alkermes, Inc. | 2 | $137 |
| Supernus Pharmaceuticals, Inc. | 2 | $108 |
| Tris Pharma Inc | 3 | $54 |
| Neos Therapeutics, LP | 3 | $53 |
Products named: Auvelity, CAPLYTA, Azstarys, REXULTI, VRAYLAR, COBENFY, LYBALVI, Qelbree.
Industry payments across FL — which companies pay providers there.
